Analyst Price Target is $9.40
▼ -3.98% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Enfusion in the last 3 months. The average price target is $9.40, with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a -3.98% upside from the last price of $9.79.
Current Consensus is
Reduce
The current consensus among 5 investment analysts is to reduce stock in Enfusion. This rating has held steady since February 2024, when it changed from a Hold consensus rating.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.
Read More
